-
公开(公告)号：US20090209034A1
公开(公告)日：2009-08-20
申请号：US12364746
申请日：2009-02-03
CPC分类号： C07K14/4748 , A61K38/00
摘要： Polypeptides comprising an unbroken sequence of amino acids from SEQ. ID. NO. 1 or 2, with an ability to complex with a major histocompatibility complex molecule type HLA-A2, and preferably HLA-A2.1.
摘要翻译： 包含SEQ ID NO：1的氨基酸序列的多肽。 ID。 没有。 1或2，具有与主要组织相容性复合分子型HLA-A2，优选HLA-A2.1复合的能力。
-
公开(公告)号：US08519109B2
公开(公告)日：2013-08-27
申请号：US12364746
申请日：2009-02-03
IPC分类号： C07H21/04
CPC分类号： C07K14/4748 , A61K38/00
摘要： Polypeptides comprising an unbroken sequence of amino acids from SEQ. ID. NO. 1 or 2, with an ability to complex with a major histocompatibility complex molecule type HLA-A2, and preferably HLA-A2.1.
摘要翻译： 包含SEQ ID NO：1的氨基酸序列的多肽。 ID。 没有。 1或2，具有与主要组织相容性复合分子型HLA-A2，优选HLA-A2.1复合的能力。
-
公开(公告)号：US07547439B1
公开(公告)日：2009-06-16
申请号：US09856812
申请日：1999-11-26
IPC分类号： A61K39/00
CPC分类号： C07K14/4748 , A61K38/00
摘要： Polypeptides comprising an unbroken sequence of amino acids from SEQ ID NO: 1 or 2, with an ability to complex with a major histocompatibility complex molecule type HLA-A2, and preferably HLA-A2.1.
摘要翻译： 包含SEQ ID NO：1或2的不间断氨基酸序列的多肽具有与主要组织相容性复合物分子型HLA-A2复合的能力，优选HLA-A2.1的能力。
-
4.发明授权Method of identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of human leukocyte antigen/tyrosinase derived peptides, and methods for treating said individuals 失效识别患有细胞异常的个体的方法，其一些异常细胞呈现人白细胞抗原/酪氨酸酶衍生肽的复合物，以及用于治疗所述个体的方法公开(公告)号：US06284476B1
公开(公告)日：2001-09-04
申请号：US08540922
申请日：1995-10-11
申请人： Thierry Boon-Falleur , Vincent Brichard , Aline Van Pel , Etienne De Plaen , Pierre Coulie , Jean-Christope Renauld , Thomas Wölfel , Bernard Lethé
发明人： Thierry Boon-Falleur , Vincent Brichard , Aline Van Pel , Etienne De Plaen , Pierre Coulie , Jean-Christope Renauld , Thomas Wölfel , Bernard Lethé
IPC分类号： G01N3353
CPC分类号： G01N33/56972 , A61K38/00 , A61K39/00 , A61K48/00 , C07K14/4748 , C07K14/535 , C07K16/243 , C12N9/0071 , C12Y114/18001 , G01N33/505 , Y10S436/813 , Y10S514/885 , Y10S530/828
摘要： The invention relates to the identification of complexes of human leukocyte antigen molecules and tyrosinase derived peptides on the surfaces of abnormal cells. The diagnostic ramifications of this observation are the subject of the invention.
摘要翻译： 本发明涉及在异常细胞表面鉴定人白细胞抗原分子和酪氨酸酶衍生肽的复合物。 该观察的诊断结果是本发明的主题。
-
5.发明授权Methods for treating subjects with disorders characterized by expression of tumor rejection antigen precursors 有权用于治疗以肿瘤排斥抗原前体表达为特征的疾病的受试者的方法公开(公告)号：US06201111B1
公开(公告)日：2001-03-13
申请号：US09224834
申请日：1999-01-04
申请人： Vincent Brichard , Aline Van Pel , Catia Traversari , Thomas Wölfel , Pierre Coulie , Thierry Boon-Falleur , Etienne De Plaen
发明人： Vincent Brichard , Aline Van Pel , Catia Traversari , Thomas Wölfel , Pierre Coulie , Thierry Boon-Falleur , Etienne De Plaen
IPC分类号： C07H2102
CPC分类号： G01N33/57484 , A61K38/00 , C07K14/4748 , C07K14/70539 , Y02P20/582
摘要： The invention relates to nucleic acid molecules coding for a tumor rejection antigen precursor. Specifically, the tumor rejection antigen precursor, or ‘TRAP”, is processed into at least one tumor rejection antigen, which is presented by HLA-A2 molecules. Ramifications of the discovery are also set forth.
摘要翻译： 本发明涉及编码肿瘤排斥抗原前体的核酸分子。 具体地，将肿瘤排斥抗原前体或“TRAP”加工成由HLA-A2分子呈递的至少一种肿瘤排斥抗原。 还发现了这一发现的发现。
-
6.发明授权Precursor processed to at least one tumor rejection antigen presented by HLA-A2 失效前体加工成由HLA-A2呈递的至少一种肿瘤排斥抗原
公开(公告)号：US6001975A
公开(公告)日：1999-12-14
申请号：US33881
申请日：1998-03-03
申请人： Vincent Brichard , Aline Van Pel , Catia Traversari , Thomas Wolfel , Thierry Boon-Falleur , Etienne De Plaen
发明人： Vincent Brichard , Aline Van Pel , Catia Traversari , Thomas Wolfel , Thierry Boon-Falleur , Etienne De Plaen
CPC分类号： C07K14/4748 , G01N33/57484
摘要： The invention relates to nucleic acid molecules coding for a tumor rejection antigen precursor. Specifically, the tumor rejection antigen precursor, or `TRAP", is processed into at least one tumor rejection antigen, which is presented by HLA-A2 molecules. Ramifications of the discovery are also set forth.
摘要翻译： 本发明涉及编码肿瘤排斥抗原前体的核酸分子。 具体地，将肿瘤排斥抗原前体或“TRAP”加工成由HLA-A2分子呈递的至少一种肿瘤排斥抗原，还阐述了发现的突变。
-
7.发明授权Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2 失效编码被HLA-A2呈递至少一种肿瘤排斥抗原的肿瘤排斥抗原前体的分离的核酸序列
公开(公告)号：US5856091A
公开(公告)日：1999-01-05
申请号：US370319
申请日：1995-01-10
申请人： Vincent Brichard , Aline Van Pel , Catia Traversari , Thomas Wolfel , Pierre Coulie , Thierry Boon-Falleur , Etienne De Plaen
发明人： Vincent Brichard , Aline Van Pel , Catia Traversari , Thomas Wolfel , Pierre Coulie , Thierry Boon-Falleur , Etienne De Plaen
IPC分类号： G01N33/50 , A61K35/14 , A61K38/00 , A61K39/00 , A61K48/00 , A61P35/00 , C07H21/04 , C07K14/47 , C07K14/725 , C07K14/74 , C12N1/21 , C12N5/10 , C12N15/09 , C12Q1/68 , G01N33/53 , G01N33/566 , G01N33/574 , C12N15/11
CPC分类号： G01N33/57484 , C07K14/4748 , C07K14/70539 , A61K38/00 , Y02P20/582
摘要： The invention relates to nucleic acid molecules coding for a tumor rejection antigen precursor. Specifically, the tumor rejection antigen precursor, or "TRAP", is processed into at least one tumor rejection antigen, which is presented by HLA-A2 molecules. Ramifications of the discovery are also set forth.
摘要翻译： 本发明涉及编码肿瘤排斥抗原前体的核酸分子。 具体地，将肿瘤排斥抗原前体或“TRAP”加工成由HLA-A2分子呈递的至少一种肿瘤排斥抗原。 还发现了这一发现的发现。
-
8.发明授权Methods for determining disorders by assaying for a non-tyrosinase, tumor rejection antigen precursor 失效通过测定非酪氨酸酶，肿瘤排斥抗原前体来测定疾病的方法
公开(公告)号：US5837476A
公开(公告)日：1998-11-17
申请号：US7966
申请日：1998-01-16
申请人： Vincent Brichard , Aline Van Pel , Catia Traversari , Thomas Wolfel , Thierry Boon-Falleur , Etienne De Plaen
发明人： Vincent Brichard , Aline Van Pel , Catia Traversari , Thomas Wolfel , Thierry Boon-Falleur , Etienne De Plaen
IPC分类号： G01N33/574 , A61K38/00 , C07H21/04 , G01N33/53
CPC分类号： G01N33/57484
摘要： The invention relates to nucleic acid molecules coding for a tumor rejection antigen precursor. Specifically, the tumor rejection antigen precursor, or `TRAP", is processed into at least one tumor rejection antigen, which is presented by HLA-A2 molecules. Ramifications of the discovery are also set forth.
摘要翻译： 本发明涉及编码肿瘤排斥抗原前体的核酸分子。 具体地，将肿瘤排斥抗原前体或“TRAP”加工成由HLA-A2分子呈递的至少一种肿瘤排斥抗原，还阐述了发现的突变。
-
9.发明授权Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2 失效编码被HLA-A2呈递至少一种肿瘤排斥抗原的肿瘤排斥抗原前体的分离的核酸序列
公开(公告)号：US5620886A
公开(公告)日：1997-04-15
申请号：US32978
申请日：1993-03-18
申请人： Vincent Brichard , Aline Van Pel , Catia Traversari , Thomas W olfel , Thierry Boon-Falleur , Etienne De Plaen
发明人： Vincent Brichard , Aline Van Pel , Catia Traversari , Thomas W olfel , Thierry Boon-Falleur , Etienne De Plaen
IPC分类号： A61K38/00 , C07H21/04 , C07K14/47 , C12N5/10 , C12N15/09 , C12P21/02 , G01N33/574 , C12N5/00 , C07H19/00 , C07K1/00 , C12P21/00
CPC分类号： C07K14/4748 , G01N33/57484 , A61K38/00
摘要： The invention relates to nucleic acid molecules coding for a tumor rejection antigen precursor. Specifically, the tumor rejection antigen precursor, or "TRAP", is processed into at least one tumor rejection antigen, which is presented by HLA-A2 molecules. Ramifications of the discovery are also set forth.
摘要翻译： 本发明涉及编码肿瘤排斥抗原前体的核酸分子。 具体地，将肿瘤排斥抗原前体或“TRAP”加工成由HLA-A2分子呈递的至少一种肿瘤排斥抗原。 还发现了这一发现的发现。
-
10.再颁专利Nucleic acid molecules encoding the MAGE-1 tumor rejection antigen precursor 失效编码MAGE-1肿瘤排斥抗原前体的核酸分子公开(公告)号：USRE40089E1
公开(公告)日：2008-02-19
申请号：US08590097
申请日：1996-01-24
申请人： Thierry Boon-Falleur , Pierre Van der Bruggen , Benoit Van den Eynde , Aline Van Pel , Etienne De Plaen , Christophe Lurquin , Patrick Chomez , Catia Traversari
发明人： Thierry Boon-Falleur , Pierre Van der Bruggen , Benoit Van den Eynde , Aline Van Pel , Etienne De Plaen , Christophe Lurquin , Patrick Chomez , Catia Traversari
CPC分类号： C07K14/4748 , A61K38/00 , A61K39/00 , C07K16/30
摘要： The invention relates to an isolated DNA sequence which codes for an antigen expressed by tumor cells which is recognized by cytotoxic T cells, leading to lysis of the tumor which expresses it. Also described are cells transfected by the DNA sequence, and various therapeutic and diagnostic uses arising out of the properties of the DNA and the antigen for which it codes.
摘要翻译： 本发明涉及编码由细胞毒性T细胞识别的肿瘤细胞表达的抗原的分离的DNA序列，导致表达肿瘤的裂解。 还描述了由DNA序列转染的细胞，以及由其编码的DNA和抗原的性质产生的各种治疗和诊断用途。
-
-
-
-
-
-
-
-
-
搜索结果
27 条记录 (耗时 0.029 秒)
